Two demand notes receivable from the founding shareholders related to the sale of common stock; no payments received and balances fully reserved.
| Officer | Age | In this role | Joined | Source |
|---|---|---|---|---|
|
Brian Carrico
Also a director
President, Chief Executive Officer, and Director
|
44 | Not stated | Not stated | |
|
Timothy Henrichs
Chief Financial Officer
|
53 |
Since 2024
2 years
|
Not stated | |
|
Adrian Miranda
CMO, SVP Science & Tech
Title from the Form 4 dated Aug 24, 2026
|
57 | Not stated | Not stated | |
|
Thomas Carrico
CRO, CCO, CPO
Title from the Form 4 dated Oct 8, 2026
|
69 | Not stated | 2012 | |
|
Craig Thomas Blanchard
Chief Commercial Officer
Title from the Form 3 dated Sep 28, 2026
|
Not stated | Not stated | Not stated |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Two demand notes receivable from the founding shareholders related to the sale of common stock; no payments received and balances fully reserved.
Exclusive license for the auricular portion of certain patents owned by the LLC; license costs incurred for patent maintenance.
Board member purchases NeuroStim devices at cost for research and development activities.
Accounting and tax services contracted on a continuous basis through a third-party public accounting firm.
Issuance of 20,000 common shares with a fair value for services rendered during the IPO process.
Loading...